info@ucallmlabs.com
Protein‑protein interaction
1. Co‑IP (Co‑Immunoprecipitation)
Co‑IP is a classical in vivo protein‑protein interaction technology developed based on the principle of Immunoprecipitation (IP). IP is a classical protein separation technique that leverages the specific recognition and binding of antibodies to target antigens, followed by isolation and purification of the antibody‑antigen complex from complex biological samples using solid‑phase carriers such as Protein A/G. The core of IP lies in “fishing out a single target protein”. It is widely applied in target protein enrichment, purity verification, post‑translational modification analysis, and protein expression level detection, serving as a foundational tool in proteomics research.
Co‑IP is a powerful protein‑protein interaction validation technology built upon the foundation of classical IP. While IP focuses on isolating a single target protein, Co‑IP extends this principle to “fish out the target protein along with its interacting partners”. The workflow begins with the lysis of cells or tissues under non‑denaturing conditions, carefully preserving endogenous protein‑protein interaction complexes in their native state. The resulting lysate is then incubated with a target‑specific antibody directed against the bait protein, enabling the co‑capture of both the bait and its specifically associated interacting partners (prey proteins). Following stringent washes to eliminate non‑specifically bound contaminants, the co‑precipitated protein complexes are eluted under denaturing conditions. The eluate is subsequently analyzed by Western blot for validation of known interactors, or by LC‑MS/MS for unbiased identification of novel interacting proteins. This approach enables indirect yet highly specific detection of proteins that associate with the target protein in its native cellular context, providing robust evidence for physiological protein‑protein interactions.
1.1 Technical Comparison
| Comparison Dimension | Endogenous Co‑IP | Tagged Protein Co‑IP |
|---|---|---|
| Physiological relevance | Native expression levels, truly reflecting physiological states; the gold standard validation method | Usually requires overexpression, may introduce non‑physiological interactions; CRISPR endogenous tagging can improve |
| Antibody dependency and applicability | Depends on high‑quality endogenous antibodies, high cost and long cycle; some proteins lack available antibodies, difficult for low‑abundance proteins | Only requires commercial tag antibodies, low cost and short cycle; theoretically applicable to all clonable proteins |
| Background and specificity | Higher background with greater non‑specific binding risk; requires strict controls (IgG, knockout cell lines) | Tag antibodies are highly specific with relatively low background; but need to exclude non‑specific interactions caused by the tag itself |
| Quantification and MS compatibility | Difficult to quantify precisely; antibody light/heavy chains interfere with MS identification | Easy to standardize quantification; tag peptide competitive elution avoids antibody contamination, highly compatible with MS |
| Applications | Validation of known interactions, clinical sample analysis, final pre‑publication validation | Large‑scale interactome screening, novel protein function study, quantitative interaction dynamics analysis |
1.2 Endogenous Co‑IP
1.2.1 Introduction
Endogenous Co‑IP refers to a technique that does not involve exogenous expression or tag fusion. Instead, it directly utilizes natively expressed proteins from cells or tissues, employing specific antibodies to perform immunoprecipitation, thereby validating protein‑protein interactions under physiological conditions. Endogenous Co‑IP can reflects authentic physiological interactions, preserves native PTMs, avoids overexpression artifacts.
1.2.2 Products
1.2.3 Applications
| Applications | Description |
|---|---|
| Protein‑protein interaction discovery | Identification of novel and known interaction partners of endogenous bait proteins under near‑physiological conditions, preserving native protein complexes and post‑translational modifications |
| Protein complex isolation and characterization | Purification of intact multi‑protein complexes (e.g., proteasome, transcription machinery, signaling scaffolds) to define stoichiometry, subunit composition, and functional architecture |
| Post‑translational modification studies | Detection of modification‑specific interactions (phosphorylation, ubiquitination, acetylation) by using PTM‑specific antibodies in Co‑IP, revealing how PTMs regulate protein binding and function |
| Transcription complex and chromatin studies | Isolation of transcription factors and their co‑regulators from endogenous chromatin environments to study gene regulatory networks, enhancer complexes, and epigenetic machinery |
| Disease mechanism and biomarker discovery | Investigating aberrant protein interactions in cancer, neurodegeneration, and autoimmune diseases to identify oncogenic complexes, disease‑specific interactomes, and potential therapeutic targets |
| Weak/transient interaction capture | Cross‑linking enhanced Co‑IP stabilizes labile interactions, enabling detection of transient signaling complexes and low‑affinity binding partners |
References:
- Knittel J, Srinivasan G, Frisch C, Brookhouser N, Raman S, Essuman A, Brafman DA. A microcarrier‑based protocol for scalable generation and purification of human induced pluripotent stem cell‑derived neurons and astrocytes. STAR Protoc. 2022 Aug 18;3(3):101632. doi: 10.1016/j.xpro.2022.101632. PMID: 36035791; PMCID: PMC9405537.
- Sciuto MR, Warnken U, Schnölzer M, Valvo C, Brunetto L, Boe A, Biffoni M, Krammer PH, De Maria R, Haas TL. Two‑Step Coimmunoprecipitation (TIP) Enables Efficient and Highly Selective Isolation of Native Protein Complexes. Mol Cell Proteomics. 2018 May;17(5):993‑1009. doi: 10.1074/mcp.O116.065920. Epub 2017 Dec 7. PMID: 29217617; PMCID: PMC5930409.
- Meeussen JVW, Pomp W, Brouwer I, de Jonge WJ, Patel HP, Lenstra TL. Transcription factor clusters enable target search but do not contribute to target gene activation. Nucleic Acids Res. 2023 Jun 23;51(11):5449‑5468. doi: 10.1093/nar/gkad227. PMID: 36987884; PMCID: PMC10287935.
- Sharifi Tabar M, Francis H, Yeo D, Bailey CG, Rasko JEJ. Mapping oncogenic protein interactions for precision medicine. Int J Cancer. 2022 Jul 1;151(1):7‑19. doi: 10.1002/ijc.33954. Epub 2022 Feb 14. PMID: 35113472; PMCID: PMC9306658.
- Shi JM, Pei J, Liu EQ, Zhang L. Bis(sulfosuccinimidyl) suberate (BS3) crosslinking analysis of the behavior of amyloid‑β peptide in solution and in phospholipid membranes. PLoS One. 2017 Mar 21;12(3):e0173871. doi: 10.1371/journal.pone.0173871. PMID: 28323849; PMCID: PMC5360245.
1.3 Tagged Protein Co‑IP
1.3.1 Introduction
Tagged Protein Co‑IP refers to a technique where a target protein is overexpressed in cells with a specific epitope tag (Flag, HA, Myc, GFP, V5, etc.) via an exogenous expression system (plasmid transfection, viral infection, etc.). Anti‑tag antibodies are then used to perform immunoprecipitation, validating interactions between the protein of interest and its binding partners.
Comparison of Common Tag Systems
| Tag | Size | Features | Applications |
|---|---|---|---|
| Flag | 8 aa (~1 kDa) | Hydrophilic, highly immunogenic, mature antibodies | Most commonly used; universal for IP/WB |
| HA | 9 aa (~1.1 kDa) | From influenza hemagglutinin; excellent specificity | Preferred for dual‑tag experiments |
| Myc | 10 aa (~1.2 kDa) | From c‑Myc; abundant polyclonal antibodies | Combined with Flag/HA for dual tagging |
| GFP | 238 aa (~27 kDa) | Enables fluorescent tracking; large size may interfere | When subcellular localization is needed |
| V5 | 14 aa (~1.6 kDa) | Low background | To avoid endogenous cross‑reactivity |
| Strep II | 8 aa (~1 kDa) | High affinity for Strep‑Tactin | High‑purity purification requirements |
Advantages:
- No endogenous antibody required: Solves the problem of many proteins lacking high‑quality IP antibodies
- High specificity: Anti‑tag antibodies are extensively optimized, low background, high reproducibility
- Standardized operation: Reproducible results across different laboratories
- Mutant introduction: Facilitates construction of point mutations, truncations for domain studies
- Multi‑tag combinations: Dual‑tag systems (Flag+HA, Flag+Myc) enable tandem affinity purification (TAP)
Limitations:
- Non‑physiological expression levels: Overexpression may cause "crowding" false positives; Tag interference: Tag may occlude interaction interfaces or alter conformation.
- Missing post‑translational modifications: Prokaryotic systems lack eukaryotic modifications.
- Competition with endogenous proteins: Exogenous proteins may compete for interaction partners.
1.3.2 Products
1.3.3 Applications
| Applications | Description |
|---|---|
| Protein‑protein interaction identification | Use tags like FLAG, HA, or His to specifically enrich bait proteins from cell lysates, then identify interacting proteins (prey) using mass spectrometry (MS) or Western blot to reveal signaling pathways and protein complex compositions. |
| Protein complex isolation and characterization | Used to isolate multi‑subunit protein complexes (such as proteasomes or transcription factor complexes), study their subunit composition, assembly order, and functional regulation. |
| Signaling pathway investigation | Study dynamic changes in protein interactions in signaling cascades, like Ras‑RAF interactions in the MAPK pathway, to uncover disease mechanisms and potential intervention targets. |
| Large‑scale interactome mapping | Overexpress tagged proteins and use quantitative mass spectrometry (like SILAC) for high‑throughput interaction screening and systematically map protein interaction networks. |
| Weak/transient interaction capture | Use chemical crosslinkers (DSP, BS3) to stabilize weak interactions, then enrich with tag‑based Co‑IP to improve detection sensitivity. |
| Post‑translational modification studies | Enrich tag‑based Co‑IP of protein complexes modified by ubiquitination, phosphorylation, SUMOylation, etc., to study how these modifications regulate interactions. |
References:
- Free RB, Hazelwood LA, Sibley DR. Identifying novel protein‑protein interactions using co‑immunoprecipitation and mass spectroscopy. Curr Protoc Neurosci. 2009 Jan;Chapter 5:Unit 5.28. doi: 10.1002/0471142301.ns0528s46. PMID: 19170023; PMCID: PMC4752115.
- van der Geer P. Analysis of protein‑protein interactions by coimmunoprecipitation. Methods Enzymol. 2014;541:35‑47. doi: 10.1016/B978‑0‑12‑420119‑4.00004‑5. PMID: 24674061.
- Lee HW, Kyung T, Yoo J, Kim T, Chung C, Ryu JY, Lee H, Park K, Lee S, Jones WD, Lim DS, Hyeon C, Heo WD, Yoon TY. Real‑time single‑molecule co‑immunoprecipitation analyses reveal cancer‑specific Ras signalling dynamics. Nat Commun. 2013;4:1505. doi: 10.1038/ncomms2507. PMID: 23422673; PMCID: PMC3586730.
- Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002 May;1(5):376‑86. doi: 10.1074/mcp.m200025‑mcp200. PMID: 12118079.